Top Page
NetScientific
(LSE:EMVC)
NetScientific (EMVC) vs. iShares MSCI United Kingdom ETF (EWC)
NetScientific Business Overview & Revenue Model
NetScientific Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.45M | 1.45M | 1.00M | 1.11M | 394.00K |
| Gross Profit | 2.09M | 1.23M | 782.00K | 989.00K | 348.00K |
| EBITDA | -3.12M | -2.27M | -3.31M | -2.65M | -2.20M |
| Net Income | -3.06M | -2.64M | -3.09M | -2.38M | -1.61M |
Balance Sheet | |||||
| Total Assets | 19.50M | 22.46M | 28.95M | 20.69M | 8.07M |
| Cash, Cash Equivalents and Short-Term Investments | 949.00K | 347.00K | 580.00K | 2.35M | 1.03M |
| Total Debt | 1.53M | 2.53M | 1.25M | 654.00K | 509.00K |
| Total Liabilities | 5.43M | 5.35M | 3.71M | 2.18M | 1.17M |
| Stockholders Equity | 15.10M | 17.83M | 25.84M | 18.50M | 6.74M |
Cash Flow | |||||
| Free Cash Flow | -1.97M | -3.51M | -3.16M | -3.54M | -2.88M |
| Operating Cash Flow | -1.78M | -3.14M | -2.56M | -3.48M | -2.79M |
| Investing Cash Flow | 12.00K | 1.11M | -1.08M | -3.46M | -959.00K |
| Financing Cash Flow | 2.57M | 1.39M | 1.74M | 8.02M | 1.89M |
NetScientific Technical Analysis
NetScientific Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £9.01M | 3.34 | 23.46% | ― | -79.36% | 78.16% | |
65 Neutral | £5.45B | 8.77 | 9.49% | 5.11% | 10.05% | -13.15% | |
58 Neutral | £14.02M | ― | -18.57% | ― | 69.55% | -12.10% | |
58 Neutral | £16.45M | ― | ― | 28.54% | 72.05% | ||
54 Neutral | £13.44M | ― | -8.99% | ― | -20.43% | -104.66% |
NetScientific Corporate Events
EMV Capital plc announced the successful passage of all resolutions at its 2025 Annual General Meeting, including the reappointment of key directors and the authorization for directors to allot securities. This outcome reflects strong shareholder support and positions the company to continue its strategic initiatives in the deep tech and life sciences sectors, potentially enhancing its market standing and value creation for stakeholders.
EMV Capital plc has entered into a licence agreement with AB Group Limited to share office space, resulting in a related party transaction due to AB Group’s substantial shareholding in EMV Capital. The agreement involves an annual rent and shared service costs, with a minimum occupancy period until December 2027. The directors, excluding those with potential conflicts of interest, have deemed the terms fair and reasonable for shareholders.
EMV Capital plc announced that its portfolio company, Q-Bot Limited, has successfully closed an initial tranche of approximately £350,000 as part of its equity fundraising program, with a total target of up to £1 million. This fundraising, led by EMV Capital Partners, will support Q-Bot’s growth strategy as it transitions to a lean technology business. EMV Capital’s conversion of a convertible loan at a discounted rate has increased its equity holding in Q-Bot to 30.2%, reflecting a significant rise in the company’s post-investment fair value. The fundraising is expected to enhance Q-Bot’s market position and profitability, benefiting both existing and new investors.
EMV Capital PLC, a UK-based company, has announced a change in its voting rights structure following an acquisition of shares by James Robert Kight. The acquisition has increased Kight’s voting rights from 4.11221% to 5.11742%, totaling 1,400,000 voting rights. This change signifies a notable shift in shareholder influence within the company, potentially impacting future decision-making processes.
EMV Capital plc has released its Annual Report and Accounts for the year ended December 31, 2024, and announced the date for its Annual General Meeting on June 30, 2025. This announcement reflects the company’s commitment to transparency and shareholder engagement, potentially impacting its operations and market positioning by reinforcing investor confidence.
EMV Capital plc announced that its CEO, Dr. Ilian Iliev, and Executive Director, Ed Hooper, have purchased a total of 52,516 ordinary shares in the company through their Self-Invested Personal Pensions. This move indicates a strong vote of confidence in the company’s future prospects by its leadership, potentially impacting investor sentiment positively and reinforcing EMV Capital’s commitment to its growth strategy.
EMV Capital plc announced its preliminary results for the year ending December 2024, highlighting a successful launch of its Fund Management practice and a significant increase in assets under management. Despite a rise in group revenue to £2.5 million, the company reported a loss of £3.7 million, attributed to core operations and subsidiary portfolio companies. The company remains optimistic about future growth, with several holdings nearing inflection points that could deliver substantial returns, positioning EMV Capital as a leading player in its sectors.
PDS Biotechnology, a portfolio company of EMV Capital, has announced significant progress in its clinical and corporate activities for the first quarter of 2025. The company initiated the VERSATILE-003 Phase 3 clinical trial for its Versamune® HPV therapy targeting HPV16-positive head and neck cancers, marking a pivotal step in addressing a growing patient population. Additionally, PDS Biotech’s financial results show a reduction in net loss and operating expenses compared to the previous year, reflecting improved financial management. The company’s advancements in clinical trials and strategic partnerships underscore its commitment to developing innovative cancer therapies, potentially enhancing its market position and offering promising implications for stakeholders.